Beclobrate is a fibric acid derivative with potent cholesterol- and triglyceride-lowering effects. The effectiveness of the drug has been investigated in a variety of studies including patients with hyperlipidemia types IIa, IIb and IV and patients suffering from secondary hyperlipidemia attributable to diabetes mellitus, liver disease, end-stage renal failure requiring hemodialysis, and kidney transplantation. In general, side-effects of beclobrate therapy are comparable with those of other fibric acid derivatives. Gastrointestinal disturbances, nausea were the major side-effects. Beclobrate has now been withdrawn from the market since the risk of hepatic damage is believed to outweigh the potential benefits of the drug.